Versant Capital Management, Inc Akebia Therapeutics, Inc. Transaction History

Versant Capital Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$2.22 - $3.78 $42 - $71	-19 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$6.67 - $13.58 $126 - $258	19 New	19 $0
Q1 2020 Apr 17, 2020	SELL	$4.1 - $10.24 $250 - $624	-61 Closed	0 $0
Q4 2019 Jan 28, 2020	BUY	$3.16 - $6.73 $192 - $410	61 New	61 $0
Q3 2019 Oct 18, 2019	SELL	$3.55 - $5.4 $205 - $313	-58 Closed	0 $0
Q2 2019 Jul 16, 2019	BUY	$4.1 - $8.05 $237 - $466	58 New	58 $0

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Versant Capital Management, Inc with notifications on news.